Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers EP News Bureau Dec 2, 2020 Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations
